Ixekizumab-induced urticarial drug eruption

Area of Science:

• Immunodermatology
• Biologic therapies for inflammatory skin conditions

Background:

• Biological agents represent advanced treatments for inflammatory skin diseases, surpassing limitations of traditional oral therapies.
• Ixekizumab, a monoclonal antibody targeting IL-17A, demonstrates significant efficacy in managing psoriasis.
• While generally well-tolerated, biologic agents can rarely induce type I allergic reactions.

Observation:

• A case study involving a patient treated with ixekizumab for psoriasis is presented.
• The patient developed urticaria, a type of hives, during treatment.

Findings:

• This report details a rare instance of ixekizumab-induced urticaria.
• The adverse reaction highlights a potential type I allergic response to this biologic agent.

Implications:

• Clinicians should be aware of the potential for rare allergic reactions, including urticaria, with ixekizumab therapy.
• Further monitoring for cutaneous adverse events in patients receiving IL-17A inhibitors is warranted.
• Understanding rare adverse events is crucial for optimizing biologic therapy in dermatology.